AMGEN PROVIDES STATEMENT ON MARITIDE PHASE 1 DATA
Amgen (NASDAQ:AMGN) has released a statement regarding the Phase 1 data of MariTide (maridebart cafraglutide, formerly AMG 133). The company affirms there is no apparent connection between MariTide administration and bone mineral density changes. Amgen maintains that the Phase 1 study results do not indicate any bone safety concerns and do not affect their confidence in MariTide's potential. The company plans to release Phase 2 topline data later this year.
Amgen (NASDAQ:AMGN) ha rilasciato una dichiarazione riguardo ai dati della Fase 1 di MariTide (maridebart cafraglutide, precedentemente noto come AMG 133). L'azienda afferma che non vi è apparente collegamento tra l'amministrazione di MariTide e i cambiamenti nella densità minerale ossea. Amgen sostiene che i risultati dello studio di Fase 1 non indicano preoccupazioni relative alla sicurezza ossea e non influenzano la loro fiducia nel potenziale di MariTide. L'azienda prevede di pubblicare i dati preliminari della Fase 2 entro la fine di quest'anno.
Amgen (NASDAQ:AMGN) ha emitido un comunicado sobre los datos de la Fase 1 de MariTide (maridebart cafraglutide, anteriormente AMG 133). La compañía afirma que no existe una conexión aparente entre la administración de MariTide y los cambios en la densidad mineral ósea. Amgen sostiene que los resultados del estudio de la Fase 1 no indican problemas de seguridad ósea y no afectan su confianza en el potencial de MariTide. La compañía planea publicar los datos preliminares de la Fase 2 más adelante este año.
Amgen (NASDAQ:AMGN)은 MariTide (maridebart cafraglutide, 이전 AMG 133)의 1상 데이터에 대한 발표를 했습니다. 회사는 MariTide 투여와 골밀도 변화 사이에 명백한 연결고리가 없다고 밝혔습니다. Amgen은 1상 연구 결과가 뼈의 안전성을 우려할 만한 것이 아니며, MariTide의 잠재력에 대한 신뢰에 영향을 미치지 않는다고 주장합니다. 회사는 올해 말에 2상 주요 데이터를 발표할 계획입니다.
Amgen (NASDAQ:AMGN) a publié une déclaration concernant les données de la Phase 1 de MariTide (maridebart cafraglutide, anciennement AMG 133). La société affirme qu’il n’existe pas de lien apparent entre l’administration de MariTide et les changements de densité minérale osseuse. Amgen soutient que les résultats de l'étude de Phase 1 n'indiquent aucune préoccupation en matière de sécurité osseuse et n'affectent pas leur confiance dans le potentiel de MariTide. L'entreprise prévoit de publier les données préliminaires de la Phase 2 plus tard cette année.
Amgen (NASDAQ:AMGN) hat eine Erklärung zu den Phase-1-Daten von MariTide (maridebart cafraglutide, früher bekannt als AMG 133) abgegeben. Das Unternehmen bestätigt, dass es keine offensichtliche Verbindung zwischen der Anwendung von MariTide und Veränderungen der Knochendichte gibt. Amgen betont, dass die Ergebnisse der Phase-1-Studie keine Bedenken hinsichtlich der Knochensicherheit aufzeigen und ihr Vertrauen in das Potenzial von MariTide nicht beeinträchtigen. Das Unternehmen plant, später in diesem Jahr die vorläufigen Daten der Phase 2 zu veröffentlichen.
- No bone safety concerns identified in Phase 1 trial
- Phase 2 topline data release scheduled for later this year
- None.
Insights
The Phase 1 safety statement regarding MariTide (maridebart cafraglutide) addresses a critical concern in the obesity treatment landscape. Bone mineral density changes have been a significant focus in weight loss medications, particularly given the experiences with other GLP-1 drugs. While this statement affirms no concerning safety signals, the real value proposition remains contingent on the upcoming Phase 2 data.
The statement's timing suggests a proactive response to market concerns, but offers new information. Phase 1 data typically focuses on safety and tolerability in small patient populations, making it preliminary in nature. The upcoming Phase 2 results will be far more decisive in determining MariTide's competitive positioning in the rapidly evolving obesity treatment market.
"As previously stated, Amgen does not see an association between the administration of MariTide and bone mineral density changes. The Phase 1 study results do not suggest any bone safety concern or change our conviction in the promise of MariTide. We look forward to sharing the Phase 2 topline data later this year."
Amgen Forward-Looking Statements
This communication contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this communication and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future.
Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints we have selected. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market.
Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the
The scientific information discussed in this news release related to our product candidates is preliminary and investigative. Such product candidates are not approved by the
CONTACT: Amgen,
Elissa Snook, 609-251-1407 (media)
Justin Claeys, 805-313-9775 (investors)
View original content to download multimedia:https://www.prnewswire.com/news-releases/amgen-provides-statement-on-maritide-phase-1-data-302303750.html
SOURCE Amgen
FAQ
What did Amgen (AMGN) say about MariTide's Phase 1 bone safety data?
When will Amgen (AMGN) release MariTide Phase 2 data?